A retrospective, single-center cohort study among 201 adults admitted with COVID-19 pneumonia revealed that risk factors associated with the development of acute respiratory distress syndrome (ARDS) and progression from ARDS to death included older age, neutrophilia, organ dysfunction, and coagulation derangement. Treatment with methylprednisolone may be beneficial for these patients.
In this systematic review and meta-analysis of randomized, controlled trials comparing administration of corticosteroids with placebo or standard supportive care in sepsis, corticosteroids were associated with reduced 28-day mortality.
In the United States, first-line treatment for chronic inflammatory demyelinating polyneuropathy (CIDP) is intravenous immunoglobulin (IVIG). Authors of this retrospective survey from Europe found that corticosteroid treatment had similar efficacy as IVIG and should be considered as first-line therapy for CIDP.
Based on outcomes measured at one and six months following optic neuritis in the context of multiple sclerosis, these investigators reported similar efficacy when comparing oral to bioequivalent doses of intravenous steroids.
A multicenter, randomized, double-blind, placebo-controlled trial involving patients with severe community-acquired pneumonia and evidence of high inflammation found less treatment failure in those who received steroids. However, in-hospital mortality did not differ between the groups.